Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study.

Hyung-Don KimYeonghak BangMyung Ah LeeJin Won KimJee Hyun KimHong Jae ChonBeodeul KangMyoung Joo KangIlhwan KimJaekyung CheonJun-Eul HwangJung Hun KangSeonggyu ByeonJung Yong HongBaek-Yeol RyooHo Yeong LimChanghoon Yoo

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

Regorafenib's poor clinical outcomes and increased frequency of severe adverse events lead us to discourage its use in the Child-Pugh B population. In particular, regorafenib should not be used in Child-Pugh B patients with ALBI grade 3.

Keyphrases

mental health
metastatic colorectal cancer
clinical trial
early onset
randomized controlled trial
study protocol
cross sectional
double blind
drug induced